MedMira Inc. (47M)

Overview

Glenmark Life Sciences Limited, rooted in Mumbai, India, and established in 2011, stands as a pivotal player in the pharmaceutical sector. It specializes in the development, manufacture, and marketing of sophisticated active pharmaceutical ingredients (APIs) that cater to chronic therapeutic areas. The company's extensive expertise covers a broad spectrum of chronic therapeutic segments including cardiovascular disease, central nervous system disorders, diabetes, gastrointestinal health, oncology, pain management, and anti-infective solutions. Serving not only the domestic market but also having a strong international presence, Glenmark Life Sciences Limited exports its premium products across Europe, North America, Latin America, and Japan. This remarkable outreach underscores the company's commitment to enhancing healthcare on a global scale. As a testament to its integrated approach and dedication to excellence, Glenmark Life Sciences Limited operates as a subsidiary of Nirma Limited, further solidifying its standing in the pharmaceutical industry.

Products and Services

• Active Pharmaceutical Ingredients (APIs):

  This category includes a diverse range of APIs like olmesartan, telmisartan, perindopril, atovaquone, solifenacin, mirabegron, sitagliptin, zonisamide, adapalene, and rosuvastatin. These APIs are crucial for manufacturing medications that target various therapeutic areas such as cardiovascular diseases, central nervous system disorders, diabetes, and more. With a focus on quality and efficacy, Glenmark Life Sciences ensures these ingredients meet the highest standards for pharmaceutical manufacturing.

• Contract Development and Manufacturing Services:

  Glenmark Life Sciences extends its pharmaceutical expertise by offering bespoke contract development and manufacturing services. These services cater to multinational corporations and specialty companies, emphasizing a collaborative approach to bring pharmaceutical products from concept to market. The company leverages its state-of-the-art facilities and extensive R&D capabilities to meet client demands for quality, efficiency, and scalability in drug development and manufacturing.